Treatment of canine Alopecia X with trilostane

Vet Dermatol. 2004 Oct;15(5):285-93. doi: 10.1111/j.1365-3164.2004.00403.x.

Abstract

Sixteen Pomeranians and eight miniature poodles presenting with clinical signs of alopecia X, elevated blood concentrations of 17-hydroxyprogesterone post stimulation with adrenocorticotropic hormone and increased urinary cortisol/creatinine ratios were treated with trilostane, a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase. Trilostane was given once or twice daily at a mean dose of 10.85 mg kg(-1) day(-1). Adrenal function was evaluated with a follow-up of 28 months in the Pomeranians and 33 months in the miniature poodles. Treatment with trilostane led to complete hair re-growth in 85% of the Pomeranians and in all of the miniature poodles within 4 to 8 weeks. No adverse events attributed to treatment with trilostane were recognized. The hair re-growth might have been the result of a down-regulation of adrenal steroids and/or of the noncompetitive inhibition of the oestrogen receptors at the hair follicle level.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 17-alpha-Hydroxyprogesterone / blood
  • 3-Hydroxysteroid Dehydrogenases / antagonists & inhibitors*
  • Administration, Oral
  • Adrenocorticotropic Hormone
  • Alopecia / drug therapy
  • Alopecia / veterinary*
  • Animals
  • Dihydrotestosterone / administration & dosage
  • Dihydrotestosterone / analogs & derivatives*
  • Dihydrotestosterone / therapeutic use*
  • Dog Diseases / blood
  • Dog Diseases / drug therapy*
  • Dog Diseases / pathology
  • Dogs
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Hydrocortisone / blood
  • Male
  • Pedigree
  • Syndrome
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Dihydrotestosterone
  • 17-alpha-Hydroxyprogesterone
  • Adrenocorticotropic Hormone
  • 3-Hydroxysteroid Dehydrogenases
  • trilostane
  • Hydrocortisone